- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Tarrytown Today
By the People, for the People
Regeneron Pharmaceuticals Shares Purchased by First Trust Advisors
Institutional investor raises stake in biopharmaceutical company
Published on Mar. 9, 2026
Got story updates? Submit your updates here. ›
First Trust Advisors LP, an institutional investor, increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.7% in the 3rd quarter, according to a recent 13F filing with the Securities and Exchange Commission. The investor now owns approximately 198,257 shares of the biopharmaceutical company's stock, valued at $111,474,000.
Why it matters
Regeneron Pharmaceuticals is a prominent biopharmaceutical company known for its innovative drug discovery technologies and pipeline of treatments for serious medical conditions. The increase in First Trust Advisors' stake suggests continued institutional investor confidence in the company's long-term prospects.
The details
According to the 13F filing, First Trust Advisors acquired an additional 14,213 shares of Regeneron Pharmaceuticals during the 3rd quarter, bringing its total ownership to approximately 0.19% of the company's outstanding shares. The institutional investor cited the biopharmaceutical company's strong performance and growth potential as reasons for the increased investment.
- First Trust Advisors raised its stake in Regeneron Pharmaceuticals during the 3rd quarter of 2026.
The players
First Trust Advisors LP
An institutional investor and asset management firm that has increased its holdings in Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals, Inc.
A U.S.-based biotechnology company that focuses on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.
The takeaway
The increased investment by First Trust Advisors in Regeneron Pharmaceuticals reflects the institutional investor's confidence in the biopharmaceutical company's long-term growth potential and its ability to continue developing innovative treatments for serious medical conditions.
